Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

Completed · Phase 2

Conditions studied: Liver Transplant, Kidney Transplant

In brief

Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.

Key facts

Study ID

NCT03527238

Run by

University of Florida

People needed

62

Starts

2018-09-21

Expected to finish

2021-08-31

Last updated by the study team

2021-12-10

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults undergoing liver and/or kidney transplantation

You may not qualify if…

• transplant patients with contraindications to tacrolimus

Where it is running

• UCLA — Los Angeles, California, United States
• UF Health at the University of Florida — Gainesville, Florida, United States
• National University of Singapore — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.